Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer
Prospective, open label, multi-dose, sequential dose escalation, single-center, Phase 1 trial
Solid Tumor|Colorectal Cancer|Sigmoid Colon Cancer|Rectosigmoid Junction Cancer|Cancer|Rectal Cancer
DRUG: GB104(Level 1)|DRUG: GB104(Level 2)|DRUG: GB104(Level 3)
Incidence of DLT(Dose-Limiting Toxicity) at week 4, 4 weeks|Incidence of Adverse Events from baseline to 8 weeks, assessed up to 8 weeks
Quantity and persistence of GB104 in fecal sample from baseline to 8 weeks, analyzed by quantitative PCR, assessed up to 8 weeks|Changes in composition of gut microbiota in fecal samples from baseline to 8 weeks, analyzed by 16S rRNA gene amplicon sequencing, assessed up to 8 weeks|Changes in immune status from baseline to 8 weeks, * Immune response activation factors(cytokine)
* Immunophenotyping of peripheral blood mononuclear cells will be performed by flow cytometry, assessed up to 8 weeks|Changes in quality of life improvement from baseline to 8 weeks, analyzed by EQ-5D-5L(EuroQoL 5-Dimensions 5-Level) questionnaire, assessed up to 8 weeks|Changes of LARS(Low Anterior Resection Syndrome) score from baseline to 8 weeks, analyzed by LARS questionnaire, assessed up to 8 weeks
This is a single center, open-label, phase 1 study to evaluate the safety and tolerability of GB104 and explore gut microbial composition in patients with colorectal cancer who completed standard treatment including curative colectomy with or without full-cycle adjuvant chemotherapy. GB104 is a live biotherapeutic product consisting of a lyophilized formulation of a single strain of bacterium. The dosing regimen for the study involves the oral administration of the experimental drug once a day.